Roivant Sciences Ltd.

Public Equity (NASDAQ)BiopharmaPublicDrug Development

📍 LONDON, X0• Founded 2014

StreetZero Signal 67

Be the first to signal interest

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that develops and commercializes medicines across multiple therapeutic areas through its network of subsidiary companies. It focuses on late-stage drug development and has brought several products to market. The company became publicly traded on NASDAQ under the ticker ROIV following a 2021 SPAC merger.

LATEST FUNDINGRule 144

$7.3M

Announced 2026-10-28

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Roivant Sciences Ltd..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED2014

HQLONDON, X0

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Publicly traded on NASDAQ (ROIV) since 2021
Operates via subsidiary model for therapeutic focus areas
$7.3M Rule 144 private placement completed

Ask StreetZero about Roivant Sciences Ltd.

Put our AI to work on this deal.

What is Roivant Sciences Ltd.'s value proposition?Who are Roivant Sciences Ltd.'s competitors?Why does this raise matter?Summarize Roivant Sciences Ltd. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.